Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
about
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Adipose tissue immunity and cancerCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusPhase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model.Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissueUsing Drosophila melanogaster to identify chemotherapy toxicity genes.Ramucirumab: preclinical research and clinical development.Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung CancerGermline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayRole of targeted agents in metastatic colorectal cancer.Complement inhibition in cancer therapy.Targeting tyrosine-kinases in ovarian cancer.Understanding and targeting resistance to anti-angiogenic therapies.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Clinical experience with ramucirumab : outcomes in breast cancer.Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.Revision of the concept of anti-angiogenesis and its applications in tumor treatment.
P2860
Q26752752-243D72CC-9E90-4F4C-8D96-5DF354304176Q26862654-6A81C0ED-EE51-426A-8A61-E8A41BA298CBQ27001560-DA869DC6-52DC-4BCF-8442-D4C1E988302AQ33418595-FD83E918-71E6-4500-8D1C-9244422ECA13Q34026969-5D65E7F5-310F-4B56-A3BD-4D14215B4CB4Q34158325-61FF13DC-34A9-4771-89E7-27800B0BBFACQ34242959-AC6BB9D5-0BBD-4CED-9FF8-567DE4411F5BQ34446310-302C0AED-9BEF-441C-817C-2597F240CDCDQ35678431-13424661-F586-4009-A66E-CB5472D9BC15Q35826391-BDB4F728-6790-4AE8-8D06-9AE14421C5A2Q36237852-9B555EF2-BD91-4EAC-8E19-1541A1FD2892Q37604560-E708E51F-0958-494A-A81F-805158B43C6AQ38104294-928CC91C-B5CE-4AAC-9E77-461B795BB7A7Q38109340-A9CFCB71-535E-4D1B-81FF-E9911F0672A9Q38118388-99F39838-AC5B-426C-8AA8-EF02199C7E70Q38133568-E45A4E36-95FF-476A-8B62-9B8D354995C3Q38148602-F844CCBD-6FF3-447A-9E90-4DA17DE74EBEQ38228982-B5AD60F3-D3FE-4304-B83C-931CE5A60339Q41764396-4D6BC356-8314-436D-B427-DA8254BAEA1CQ49852158-68046838-66EE-49D7-BBB5-4863C76781BAQ52904940-E83817C1-FD60-4C74-83CD-B518D5BD44C6
P2860
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@ast
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@en
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@nl
type
label
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@ast
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@en
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@nl
prefLabel
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@ast
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@en
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@nl
P2093
P2860
P3181
P1433
P1476
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
@en
P2093
Bryan P Schneider
Kathy D Miller
P2860
P304
P3181
P356
10.1016/S1470-2045(12)70275-9
P407
P577
2012-10-01T00:00:00Z